AR and prostate carcinoma: We next examined the effects of VT-464 and abiraterone on the AR reporter (FKBP51-ARE-luciferase) activity with overexpression of wild-type AR, two mutant ARs, (Fig. 6A,B) and AR-V7 (Supplementary Figure 6) in AR-negative PC3 prostate cancer cells.